NY-BOTIFY
13.12.2022 10:01:55 CET | Business Wire | Press release
Botify, the leading enterprise software company for performance-driven organic search, is closing out 2022 by appointing a series of global executive hires and company advisors. The decision comes in response to continued industry and company growth, illustrating the company’s commitment to driving innovation, delivering excellence across all areas of the business and supporting customers with every opportunity to leverage organic search as a high-impact performance marketing channel.
“I’m thrilled to welcome Brian Marin, Phil Young, Vincent Gonnot, A.J. Ghergich, and Steve Sadove to Botify as we expand how we help global brands improve how they are found in organic search,” said Botify CEO, Adrien Menard. “Each of these leaders will be extremely instrumental in supporting our continued growth and new announcements in the coming months. As we embrace widespread recognition of the impact organic search has on company performance, and define Botify’s next chapter to meet growing demand, I’m confident that together, we will do great things.”
Former Smartly.io executive Brian Marin joined in August as Senior Vice President of Global Services. In this newly created role, Marin will launch a consulting service practice and expand professional services to meet continued customer demand. A seasoned digital marketer, Marin brings decades of SaaS experience and a proven track record building and leading services functions for companies in hyper-growth mode.
Joining Marin’s growing team, Botify welcomed A.J. Ghergich as Vice President of Consulting Services to lead the rollout of Botify’s new consulting service offering. Ghergich brings more than 15 years of organic search and digital marketing experience consulting for Fortune 500 global brands.
Phil Young, Vice President of Sales of Northern Europe, joined Botify in July, focusing on leading sales teams across Northern Europe including the UK, Denmark, Finland, Sweden, and the Netherlands. Young will be working closely with the marketing and product teams to drive growth and ensure the highest success level for his teams. Young brings more than 25 years’ experience driving sales results and joins Botify from Sitecore, the leading provider of end-to-end digital experience software, where he was Area Vice President of Northern EMEA.
Focusing on European expansion, Vincent Gonnot also joined Botify as Vice President of Sales Central/South EMEA in December. Similar to Young, Gonnot will be working alongside the marketing and product teams to ensure optimal regional growth for the company. Gonnot has more than 20 years of international sales and management experience across large companies and startups.
Additionally, Steve Sadove, Principal at Stephen Sadove and Associates, has joined Botify as an advisor, helping to provide high-level counsel to inform the company’s continued growth trajectory. Throughout his career serving as CEO of several retail and consumer brands, Sadove has mastered a deep understanding of how leveraging the right technologies can transform the entire landscape for a business. He will be instrumental in helping Botify achieve amplified success as an essential solution across global organizations.
About Botify
Botify is a global, enterprise software company focused on enabling the most ambitious brands to leverage organic search as a high-impact, performance marketing channel. Powered by AI and a proprietary unified data model, Botify’s platform ensures web and mobile sites are optimized for search, the foundation of being found by consumers in today’s dynamic digital environment. As the leader in organic search innovation, Botify is trusted by more than 500 of the world’s most visible brands, including Expedia, L'Oréal, Crate & Barrel, and The New York Times, all of whom have succeeded in leveraging organic search for exponential, long-term results and revenue growth.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221213005241/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom